AIM ImmunoTech (NYSE American: AIM) announced the latest in a growing body of positive data from its lead clinical program, Ampligen, for the treatment of pancreatic cancer (PC), in a presentation at the 5th Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care in Warsaw, Poland.
According to AIM, Ampligen has demonstrated data-driven promise in progression-free survival and overall survival in both the ongoing Phase 2 DURIPANC clinical trial and an early access program.
In a statement, Thomas K. Equels, CEO of AIM, commented, “Ampligen continues to demonstrate its potential for the treatment of late-stage metastatic and locally advanced pancreatic cancer. Our growing body of positive data continues to bolster our confidence. This lethal malignancy is a high unmet need. In particular, the progression-free survival and overall survival—which are the gold standards for drug approval—seen in the clinical data demonstrated to date underscore our strong belief in the potential. I am pleased to be a part of this gathering of global regulatory leaders, world-renowned oncologists and biopharma industry to share this important progress with Ampligen and highlight its potential in late-stage pancreatic cancer. We look forward to advancing its development and remain committed to bringing it to patients in desperate need and without real hope.”
